JP2011168588A5 - - Google Patents

Download PDF

Info

Publication number
JP2011168588A5
JP2011168588A5 JP2011026980A JP2011026980A JP2011168588A5 JP 2011168588 A5 JP2011168588 A5 JP 2011168588A5 JP 2011026980 A JP2011026980 A JP 2011026980A JP 2011026980 A JP2011026980 A JP 2011026980A JP 2011168588 A5 JP2011168588 A5 JP 2011168588A5
Authority
JP
Japan
Prior art keywords
gene
compound
apoptosis inducer
test compound
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011026980A
Other languages
English (en)
Japanese (ja)
Other versions
JP5213972B2 (ja
JP2011168588A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2011026980A priority Critical patent/JP5213972B2/ja
Priority claimed from JP2011026980A external-priority patent/JP5213972B2/ja
Publication of JP2011168588A publication Critical patent/JP2011168588A/ja
Publication of JP2011168588A5 publication Critical patent/JP2011168588A5/ja
Application granted granted Critical
Publication of JP5213972B2 publication Critical patent/JP5213972B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2011026980A 2004-04-09 2011-02-10 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤 Expired - Fee Related JP5213972B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2011026980A JP5213972B2 (ja) 2004-04-09 2011-02-10 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004115404 2004-04-09
JP2004115404 2004-04-09
JP2011026980A JP5213972B2 (ja) 2004-04-09 2011-02-10 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006512126A Division JP4761389B2 (ja) 2004-04-09 2005-04-08 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012046652A Division JP5390653B2 (ja) 2004-04-09 2012-03-02 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤

Publications (3)

Publication Number Publication Date
JP2011168588A JP2011168588A (ja) 2011-09-01
JP2011168588A5 true JP2011168588A5 (enExample) 2012-04-19
JP5213972B2 JP5213972B2 (ja) 2013-06-19

Family

ID=35124844

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006512126A Expired - Fee Related JP4761389B2 (ja) 2004-04-09 2005-04-08 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤
JP2011026980A Expired - Fee Related JP5213972B2 (ja) 2004-04-09 2011-02-10 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤
JP2012046652A Expired - Fee Related JP5390653B2 (ja) 2004-04-09 2012-03-02 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006512126A Expired - Fee Related JP4761389B2 (ja) 2004-04-09 2005-04-08 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012046652A Expired - Fee Related JP5390653B2 (ja) 2004-04-09 2012-03-02 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤

Country Status (5)

Country Link
US (3) US8193332B2 (enExample)
EP (4) EP2520652B1 (enExample)
JP (3) JP4761389B2 (enExample)
KR (1) KR101234281B1 (enExample)
WO (1) WO2005097189A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1625853B1 (en) * 2003-05-19 2015-07-08 Genecare Research Institute Co., Ltd Apoptosis inducer for cancer cell
US8193332B2 (en) 2004-04-09 2012-06-05 Genecare Research Institute Co., Ltd. Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes
JP4809240B2 (ja) 2004-11-19 2011-11-09 株式会社ジーンケア研究所 癌細胞特異的細胞増殖抑制剤
WO2006084694A2 (en) * 2005-02-10 2006-08-17 Centre National De La Recherche Scientifique Use of the mcm8 gene for the preparation of a pharmaceutical composition
CN101283279A (zh) * 2005-07-29 2008-10-08 肿瘤疗法科学股份有限公司 以cdca1-kntc2复合物为靶标的筛选和nsclc治疗方法
GB0606096D0 (en) 2006-03-27 2006-05-03 Cbmm Sa Screening method
WO2008047574A1 (fr) * 2006-09-28 2008-04-24 Genecare Research Institute Co., Ltd. Sensibilisateur pour agent anticancéreux
JP4940412B2 (ja) * 2006-10-16 2012-05-30 財団法人ヒューマンサイエンス振興財団 抗癌性物質のスクリーニング方法
AU2007313551A1 (en) * 2006-10-17 2008-04-24 Synergenz Bioscience Limited Methods and compositions for assessment of pulmonary function and disorders
TWI615403B (zh) * 2007-02-21 2018-02-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
EP2350278A2 (en) * 2008-09-23 2011-08-03 Silence Therapeutics AG Means for inhibiting the expression of orc-1
WO2010045526A1 (en) * 2008-10-17 2010-04-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Geminin inhibitors as tumor treatment
CN108042560A (zh) * 2008-12-04 2018-05-18 库尔纳公司 通过抑制针对沉默调节蛋白1的天然反义转录物来治疗沉默调节蛋白1相关的疾病
EP2403946A4 (en) * 2009-03-04 2012-11-14 TREATMENT OF SIRTUIN 1 (SIRT1) -HANDLED ILLNESSES BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPT AGAINST SIRT 1
US20110097329A1 (en) 2009-06-26 2011-04-28 Massachusetts Institute Of Technology Compositions and methods for treating cancer and modulating stress granule formation
US8435961B2 (en) * 2009-06-26 2013-05-07 Massachusetts Institute Of Technology Methods and compositions for increasing the activity of inhibitory RNA
US8268550B2 (en) * 2009-06-26 2012-09-18 Massachusetts Institute Of Technology Compositions and methods for identification of PARP function, inhibitors, and activators
EP2985348B1 (en) * 2009-07-24 2020-12-30 CuRNA, Inc. Treatment of sirtuin 6 (sirt6) related diseases by inhibition of natural antisense transcript to sirt6
SI2540728T1 (sl) 2010-02-17 2019-06-28 Takeda Pharmaceutical Company Limited Heterociklična spojina
US20130071395A1 (en) * 2010-05-28 2013-03-21 Case Western Reserve University Compositions and methods for treating pathologies
WO2012090479A1 (en) * 2010-12-28 2012-07-05 Oncotherapy Science, Inc. Mcm7 as a target gene for cancer therapy and diagnosis
WO2013142817A2 (en) 2012-03-23 2013-09-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
CA3136093C (en) * 2012-06-29 2025-07-08 Celgene Corporation METHODS FOR DETERMINING THE EFFICACY OF A DRUG USING PROTEINS ASSOCIATED WITH CEREBLON
US9512486B2 (en) * 2012-08-06 2016-12-06 The Institute Of Cancer Research: Royal Cancer Hospital Materials, methods, and systems for treating cancer
TWI658049B (zh) 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
KR101623814B1 (ko) 2014-02-21 2016-05-24 두산중공업 주식회사 수냉각 발전기의 분리형 냉각수 순환 구조 및 그에 따른 냉각 방법
JP2015167527A (ja) * 2014-03-07 2015-09-28 学校法人東京理科大学 標的タンパク質の量の低減のためのポリペプチド、単離された核酸、組み換えベクター、及び形質転換体
EP3237444B1 (en) * 2014-12-23 2020-05-06 Centre National De La Recherche Scientifique Use of rad18 inhibitors in the treatment of tumors
CN104673801B (zh) * 2015-02-12 2018-09-11 中山大学附属第三医院 一种肝癌基因ndc80及其应用
EP4060344A1 (en) 2015-06-08 2022-09-21 Arquer Diagnostics Limited Methods and kits
JP6854246B2 (ja) 2015-06-08 2021-04-07 アーケア ダイアグノスティクス リミテッド 尿サンプルの分析方法
EP3512535A4 (en) * 2016-09-13 2020-05-06 The Jackson Laboratory TARGETED IMPROVED DNA DEMETHYLATION
WO2018079287A1 (ja) * 2016-10-26 2018-05-03 デンカ株式会社 変異型ヒトＤＮＡポリメラーゼε
WO2019005754A1 (en) * 2017-06-26 2019-01-03 The Cleveland Clinic Foundation TREATMENT AGAINST CANCER
JP7410154B2 (ja) * 2018-09-12 2024-01-09 インスティチュート フォー ベーシック サイエンス 遺伝的に変異された細胞の死滅誘導組成物及び該組成物を用いた遺伝的に変異された細胞の死滅誘導方法
JP2022020872A (ja) * 2020-06-01 2022-02-02 均 石井 抗がん剤。

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997047971A1 (en) * 1996-06-11 1997-12-18 Advanced Research & Technology Institute Methods and compositions for the use of apurinic/apyrimidinic endonucleases
GB0004193D0 (en) * 2000-02-22 2000-04-12 Isis Innovation A genetic determinant for malignant melanoma
WO2002009573A2 (en) * 2000-07-31 2002-02-07 The Brigham And Women's Hospital, Inc. Prognostic classification of endometrial cancer
KR100909681B1 (ko) 2000-12-01 2009-07-29 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
US7892730B2 (en) * 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
US7241743B2 (en) * 2001-06-15 2007-07-10 The Trustees Of Columbia University In The City Of New York Sir2α-based therapeutic and prophylactic methods
WO2003046207A2 (en) 2001-11-27 2003-06-05 Fred Hutchinson Cancer Research Center Methods for inhibiting deacetylase activity
AU2003207708A1 (en) * 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
AU2003250831A1 (en) * 2002-06-12 2003-12-31 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of hec1 antagonists in the treatment of proliferative disorders and cancer
WO2004033666A2 (en) * 2002-10-11 2004-04-22 Board Of Regents, The University Of Texas System Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
US8090542B2 (en) * 2002-11-14 2012-01-03 Dharmacon Inc. Functional and hyperfunctional siRNA
EP1620573A4 (en) * 2003-04-15 2006-12-20 Avalon Pharmaceuticals DETERMINATION OF CANCER-ASSOCIATED GENES AND THERAPEUTIC OBJECTS USING MOLECULAR CYTOGENETIC PROCEDURES
AU2003224132A1 (en) * 2003-04-24 2004-11-19 Galapagos Genomics N.V. Effective sirna knock-down constructs
EP1625853B1 (en) * 2003-05-19 2015-07-08 Genecare Research Institute Co., Ltd Apoptosis inducer for cancer cell
US8193332B2 (en) 2004-04-09 2012-06-05 Genecare Research Institute Co., Ltd. Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes
JP4809240B2 (ja) * 2004-11-19 2011-11-09 株式会社ジーンケア研究所 癌細胞特異的細胞増殖抑制剤

Similar Documents

Publication Publication Date Title
JP2011168588A5 (enExample)
Zhang et al. Hsa_circ_0020397 regulates colorectal cancer cell viability, apoptosis and invasion by promoting the expression of the miR‐138 targets TERT and PD‐L1
JP2011037847A5 (enExample)
Li et al. Long non‐coding RNA FOXP 4‐AS 1 is an unfavourable prognostic factor and regulates proliferation and apoptosis in colorectal cancer
Schmitt et al. Long noncoding RNAs in cancer pathways
Yu et al. Downregulation of miR‐29 contributes to cisplatin resistance of ovarian cancer cells
Neudecker et al. Emerging roles for microRNAs in perioperative medicine
Wang et al. microRNA-200c modulates the epithelial-to-mesenchymal transition in human renal cell carcinoma metastasis
Xue et al. MicroRNA-targeted therapeutics for lung cancer treatment
Wang et al. miR-197: A novel biomarker for cancers
Yang et al. The emerging roles of circular RNAs in ovarian cancer
Wang et al. Upregulation of microRNA-524-5p enhances the cisplatin sensitivity of gastric cancer cells by modulating proliferation and metastasis via targeting SOX9
JP2011162558A5 (enExample)
WO2014022826A3 (en) Biomarker associated with risk of melanoma reoccurrence
JP2012050449A5 (enExample)
NZ617003A (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
BR112014029274A2 (pt) anticorpo isolado, composição farmacêutica, uso do anticorpo, método para tratar infecção rábica, kit para tratar infecção rábica, kit para detectar vírus rábico, ácido nucleico isolado, e, célula hospedeira.
Tong et al. Retracted: Long noncoding RNA NORAD is upregulated in epithelial ovarian cancer and its downregulation suppressed cancer cell functions by competing with miR‐155‐5p
WO2014162008A3 (en) Biomarker signatures for predicting drug response in hodkin's lymphoma
JP2014221834A5 (enExample)
Wan et al. MicroRNA-155 enhances the activation of Wnt/β-catenin signaling in colorectal carcinoma by suppressing HMG-box transcription factor 1 Retraction in/10.3892/mmr. 2022.12597
Ding et al. HCV infection induces the upregulation of miR-221 in NF-κB dependent manner
JP2016506412A5 (enExample)
Xie et al. Circular RNA: a new expectation for cardiovascular diseases
WO2013103984A3 (en) Use of galectin-3 for risk assessment and detection of preeclampsia and related conditions